Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience

#1297

Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.

Aim(s): We retrospectively analyze the treatment outcomes of these agents for patients (pts) with GEP-NET.

Materials and methods: Between March 2007 and October 2014, a total of 44 GEP-NET pts treated with everolimus or sunitinib were identified. Considering distinct characteristics between pancreatic (Pan) and non-Pan NETs, efficacy analysis was performed separately, while safety analysis included all pts.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Yoo C

Authors: Yoo C, Cho H, Kim K, Chang H, Kim T,

Keywords: everolimus, sunitinib, gastroenteropancreatic NET,

To read the full abstract, please log into your ENETS Member account.